Sirnaomics Company Description

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs.

The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections.

Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors.

The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases.

In addition, it is developing STP247G to treat complement-mediated immunologic diseases; STP237G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension.

The company was founded in 2007 and is based in Wan Chai, Hong Kong.

Sirnaomics Ltd.

Country	Cayman Islands
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	52
CEO	Hung Fai Poon

Contact Details

Address: Hopewell Centre Wan Chai Hong Kong
Website	sirnaomics.com

Stock Details

Ticker Symbol	2257
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	KYG2050P1028
SIC Code	2836

Key Executives

Name	Position
Dr. Hung Fai Poon Ph.D.	Chief Executive Officer and Executive Director
Dr. Yang Lu Ph.D.	Honorary Scientific Scientific Officer
Dr. Yongxiang Wang	Chief Production Officer
Yun Ting Yuen	Company Secretary